Gold prices bounce off 3-week lows; demand likely longer term
John Sakys, Chief Financial Officer of Mesa Laboratories INC /CO/ (NASDAQ:MLAB), sold 642 shares of common stock on June 16 at a price of $97.118, totaling $62,349. The sale comes as Mesa Labs, with a market capitalization of $515 million, has seen its stock decline by 11% over the past week, according to InvestingPro data.
According to a Form 4 filing with the Securities and Exchange Commission, Sakys also acquired 793 shares of Mesa Labs’ common stock on June 15 upon the exercise of restricted stock units. Additionally, 668 shares were acquired on June 15 related to performance share units. InvestingPro analysis shows Mesa Labs maintains a GOOD financial health score and has consistently paid dividends for 23 consecutive years. InvestingPro subscribers have access to 7 additional key insights about Mesa Labs’ financial performance and valuation.
In other recent news, Mesa Laboratories, Inc. has announced a change in its independent registered public accounting firm following the merger of its previous auditor, Moss Adams LLP, with Baker Tilly US, LLP. This transition was approved by the Audit Committee of Mesa Laboratories’ Board of Directors, appointing Baker Tilly as the new auditor. There were no adverse opinions or disagreements between Mesa Laboratories and Moss Adams regarding accounting practices during the fiscal year ending March 31, 2025. Additionally, Mesa Laboratories declared a quarterly dividend of $0.16 per share, scheduled for payment on June 16, 2025, to shareholders recorded as of May 30, 2025. The company has issued forward-looking statements indicating expectations of revenue growth and operational results, although it cautions that actual outcomes may differ due to various risks and uncertainties. These statements cover topics such as profit margins, industry conditions, and integration of acquired businesses. Investors are advised to consider these potential variances as detailed in Mesa’s Annual Report and other SEC filings. Mesa Laboratories continues to communicate financial developments as part of its capital allocation strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.